Drug Profile
Bidridistrogene xeboparvovec - Myonexus Therapeutics
Alternative Names: MYO-101; rAAVrh74.MHCK7.hSGCB; rAAVrh74.MHCK7.SGCB; scAAVrh74.MHCK7.hSGCB; scAAVrh74.tMCK.hSGCB; SRP-9003Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Nationwide Children's Hospital
- Developer Myonexus Therapeutics; Nationwide Children's Hospital; Sarepta Therapeutics
- Class Gene therapies
- Mechanism of Action Sarcoglycan expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Limb girdle muscular dystrophies
Most Recent Events
- 15 Jan 2024 Phase-III clinical trials in Limb girdle muscular dystrophies (In adolescents, In children, In the elderly, In adults) in USA (IV) (NCT06246513)
- 17 Feb 2023 Sarepta Therapeutics plans a global phase III trial for Limb girdle muscular dystrophies in 2023 (IV) (NCT06246513)
- 17 Feb 2023 Phase-I clinical trials in Limb girdle muscular dystrophies (In adolescents, In children, In the elderly, In adults) in USA (IV)